Trial · NCT02334722

1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients

NCT02334722, Phase 4, Completed, University of Florida; results first posted 2021-12-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients. Trials, record NCT02334722. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02334722

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
NCT number: NCT02334722
Status: Completed
Phases: Phase 4
Enrollment: 81 participants, actual
Lead sponsor: University of Florida
Conditions: Brain Neoplasms, Brain Cancer, Brain Tumors, Cancer of the Brain, Cancer of Brain, Seizure
Interventions: Levetiracetam
First posted: 2015-01-08
Last updated: 2021-12-15
Results first posted: 2021-12-15

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Neurotoxicity Scale Scores	Baseline to 6 weeks	The Neurotoxicity Scale is as a validated 27 question, patient-reported measure for assessing the adverse effects of antiepileptic drugs on cognitive function. Patients self-report "no problem", "a mild problem", "a moderate problem" or "a serious problem" for each question corresponding to a score of 0, 1, 2, and 3, respectively. For each patient, the overall score was formed by summing scores in all 27 questions. The minimum possible score is 0 and the maximum possible total score is 81. A lower score indicates less toxicity when taking an antiepileptic drug. The outcome is a score change from baseline at the 6 week follow-up and is calculated by subtracting the baseline score from the 6 week follow-up score for each patient.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Neurotoxicity Scale Scores	Baseline to 6 weeks	All patients taking levetiracetam 1000 mg daily, not stratified by dosing schedule.	score on scale	MEDIAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Neurotoxicity Scale Scores	1 Week Levetiracetam		-1	Full Range -22 to 38	score on scale
Change in Neurotoxicity Scale Scores	6 Week Levetiracetam		-3.5	Full Range -18 to 38	score on scale

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	1 Week Levetiracetam	40
Overall Study	STARTED	6 Week Levetiracetam	41
Overall Study	COMPLETED	1 Week Levetiracetam	33
Overall Study	COMPLETED	6 Week Levetiracetam	34
Overall Study	NOT COMPLETED	1 Week Levetiracetam	7
Overall Study	NOT COMPLETED	6 Week Levetiracetam	7

Source ClinicalTrials.gov

Adverse events62

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Fatigue	General disorders	1 Week Levetiracetam	6	39	7
other	Fatigue	General disorders	6 Week Levetiracetam	8	37	9
other	Headache	Nervous system disorders	1 Week Levetiracetam	9	39	9
other	Headache	Nervous system disorders	6 Week Levetiracetam	6	37	6
other	Confusion	Nervous system disorders	1 Week Levetiracetam	3	39	4
other	Confusion	Nervous system disorders	6 Week Levetiracetam	5	37	6
other	Constipation	Gastrointestinal disorders	1 Week Levetiracetam	3	39	3
other	Constipation	Gastrointestinal disorders	6 Week Levetiracetam	1	37	1
other	Insomnia	Psychiatric disorders	1 Week Levetiracetam	2	39	2
other	Insomnia	Psychiatric disorders	6 Week Levetiracetam	4	37	4

1 to 10 of 62Source ClinicalTrials.gov

See all 62 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	1 Week Levetiracetam	2	40
Total, all-cause mortality	6 Week Levetiracetam	0	41
Total, other adverse events	1 Week Levetiracetam	27	39
Total, other adverse events	6 Week Levetiracetam	22	37
Total, serious adverse events	1 Week Levetiracetam	11	39
Total, serious adverse events	6 Week Levetiracetam	7	37

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
1 Week Levetiracetam vs 6 Week Levetiracetam: deaths from any cause	Trial comparisons
1 Week Levetiracetam vs 6 Week Levetiracetam: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02334722

GET https://conductscience.org/api/trials/v1/NCT02334722/events?page=2

API reference For AI assistants